JP2013507935A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507935A5 JP2013507935A5 JP2012534414A JP2012534414A JP2013507935A5 JP 2013507935 A5 JP2013507935 A5 JP 2013507935A5 JP 2012534414 A JP2012534414 A JP 2012534414A JP 2012534414 A JP2012534414 A JP 2012534414A JP 2013507935 A5 JP2013507935 A5 JP 2013507935A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- essential
- seq
- mva virus
- orf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 21
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108700026244 Open Reading Frames Proteins 0.000 claims 8
- 108091026890 Coding region Proteins 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108091029795 Intergenic region Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 101710091045 Envelope protein Proteins 0.000 claims 1
- 108700039887 Essential Genes Proteins 0.000 claims 1
- 101710188315 Protein X Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 108091008146 restriction endonucleases Proteins 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25232609P | 2009-10-16 | 2009-10-16 | |
| US61/252,326 | 2009-10-16 | ||
| PCT/US2010/052929 WO2011047324A1 (en) | 2009-10-16 | 2010-10-15 | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507935A JP2013507935A (ja) | 2013-03-07 |
| JP2013507935A5 true JP2013507935A5 (https=) | 2013-10-31 |
| JP5789263B2 JP5789263B2 (ja) | 2015-10-07 |
Family
ID=43297031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534414A Active JP5789263B2 (ja) | 2009-10-16 | 2010-10-15 | 再構築された挿入部位を含有する組換え改変ワクシニアアンカラ（ｍｖａ）ワクシニアウイルス |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9133480B2 (https=) |
| EP (1) | EP2488649B1 (https=) |
| JP (1) | JP5789263B2 (https=) |
| AU (1) | AU2010306559B2 (https=) |
| CA (1) | CA2777744C (https=) |
| DK (1) | DK2488649T3 (https=) |
| WO (1) | WO2011047324A1 (https=) |
| ZA (1) | ZA201203551B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2062023T4 (en) * | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| WO2011047324A1 (en) | 2009-10-16 | 2011-04-21 | The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| EP3198017B1 (en) | 2014-09-26 | 2021-01-06 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Virus-based expression vectors and uses thereof |
| US11701418B2 (en) | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| US20190038659A1 (en) | 2015-09-29 | 2019-02-07 | The Usa, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating and preventing amyotrophic lateral sclerosis |
| EP3402802B1 (en) * | 2016-01-08 | 2023-04-12 | Geovax, Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| BR112018015696A2 (pt) | 2016-02-03 | 2018-12-26 | Geovax Inc | composições e métodos para gerar uma resposta imune para um flavivírus |
| EP3463448A4 (en) * | 2016-05-30 | 2020-03-11 | Geovax Inc. | Compositions and methods for generating an immune response to hepatitis b virus |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| WO2019152746A2 (en) | 2018-01-30 | 2019-08-08 | Emory University | Compositions and methods for promoting immune responses to human immunodeficiency virus |
| EP3790578A4 (en) | 2018-05-11 | 2022-04-06 | City of Hope | Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof |
| AU2020361337B2 (en) * | 2019-10-02 | 2025-02-06 | Bionoxx Inc. | Tumor-targeting protein or fragment thereof, antibody binding thereto and use thereof |
| CA3161633A1 (en) | 2019-11-14 | 2021-05-20 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| JP2023513611A (ja) | 2020-02-14 | 2023-03-31 | ゲオバックス インコーポレイテッド | Ｓａｒｓ－ｃｏｖ２に対する免疫応答を誘導するためのワクチン及びその利用 |
| JP7788403B2 (ja) | 2020-05-17 | 2025-12-18 | シティ・オブ・ホープ | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
| MX2023009008A (es) | 2021-02-02 | 2023-10-05 | Geovax Inc | Constructos virales para usarse en potenciar el cebado de linfocitos t durante la vacunación. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102703393A (zh) | 2002-05-16 | 2012-10-03 | 巴法里安诺迪克有限公司 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| AU2004226345B2 (en) | 2003-03-28 | 2011-12-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | MVA virus expressing modified HIV envelope, gag, and pol genes |
| DK2062023T4 (en) * | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| EP2199400A1 (en) * | 2008-12-22 | 2010-06-23 | Emergent Product Development Germany GmbH | Single recombination system and methods of use |
| WO2011047324A1 (en) | 2009-10-16 | 2011-04-21 | The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
-
2010
- 2010-10-15 WO PCT/US2010/052929 patent/WO2011047324A1/en not_active Ceased
- 2010-10-15 US US13/502,205 patent/US9133480B2/en active Active
- 2010-10-15 EP EP10771611.0A patent/EP2488649B1/en active Active
- 2010-10-15 AU AU2010306559A patent/AU2010306559B2/en active Active
- 2010-10-15 CA CA2777744A patent/CA2777744C/en active Active
- 2010-10-15 JP JP2012534414A patent/JP5789263B2/ja active Active
- 2010-10-15 DK DK10771611.0T patent/DK2488649T3/da active
-
2012
- 2012-05-15 ZA ZA2012/03551A patent/ZA201203551B/en unknown
-
2015
- 2015-08-27 US US14/837,382 patent/US9879231B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507935A5 (https=) | ||
| Yang et al. | Pervasive initiation and 3′-end formation of poxvirus postreplicative RNAs | |
| JP2011004755A5 (https=) | ||
| JP2010259446A5 (https=) | ||
| HRP20180146T1 (hr) | Vektori i sljedovi namijenjeni liječenju bolesti | |
| JP2014516536A5 (https=) | ||
| JP2012509678A5 (https=) | ||
| RU2018122636A (ru) | Стабильные клеточные линии для продуцирования ретровирусов | |
| CN105861558A (zh) | 一种痘苗病毒穿梭载体及其制备方法和应用 | |
| Flick et al. | Functional analysis of the noncoding regions of the Uukuniemi virus (Bunyaviridae) RNA segments | |
| JP2013538554A5 (https=) | ||
| JP2012531205A5 (https=) | ||
| CN118234850A (zh) | 利用微rna来下调经修饰的安卡拉痘苗病毒(mva)的细胞毒性转基因的表达 | |
| CN104195154B (zh) | 新城疫病毒Mukteswar中等毒力疫苗株反向遗传操作系统及其应用 | |
| CN105274142B (zh) | 复制型重组人55型腺病毒载体及其制备方法和应用 | |
| CA2909225C (en) | Mutant vaccinia virus strains, uses thereof and method of producing the same | |
| RU2011137404A (ru) | Варианты гемагглютинина и нейраминидазы гриппа | |
| CN113736799B (zh) | 山羊副流感病毒3型感染性cDNA克隆构建方法及其应用 | |
| RU2014129220A (ru) | Новый аттенуированный полиовирус: pv-1 mono-cre-x | |
| US20080267992A1 (en) | Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine | |
| CN101402945A (zh) | 表达抗传染性法氏囊病病毒微小rna重组禽腺联病毒的制备方法 | |
| CN106011087B (zh) | S1基因和tm-1基因重组腺病毒的构建方法及重组腺病毒和应用 | |
| CN104789598B (zh) | 一种表达红色荧光蛋白的重组家蚕质型多角体病毒的构建方法 | |
| CN117511888A (zh) | 一种基于CRISPR-Cas9技术的表达鸡传染性贫血病病毒T1P6毒株VP2蛋白的重组血清4型禽腺病毒及其制备方法 | |
| KR101677231B1 (ko) | 무혈청배지（serum free medium）를 이용한 메갈로사이티바이러스의 효율적 제조방법 |